Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00082667 · ClinicalTrials.gov registry record · Phase 2
Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast
A Phase 2 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT00082667 is a Phase 2 study that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 1 participants.
The verdict
NCT00082667, a Phase 2 study, was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether surgery is more effective with or without gefitinib in treating ductal carcinoma in situ. PURPOSE: This randomized phase II trial is studying how well gefitinib together with surgery works compared to surgery alone for the treatment of women with ductal carcinoma in situ of the breast.
Interventions
- PROCEDURE Surgery
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2002-10 |
| Est. Completion | 2005-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00082667
The ClinicalTrials.gov registry entry for NCT00082667 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Surgery is the first listed.
NCT00082667 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00082667 about?
NCT00082667 is a clinical study titled "Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast". RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether surgery is more effective with or without gefitinib in treating ductal carcinoma in situ. PURPOSE: This randomized phase II trial is studying how well gefitinib to...
What is the current status of trial NCT00082667?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2002-10. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00082667?
The interventions under investigation include: Surgery (PROCEDURE), gefitinib (DRUG).
Who is sponsoring clinical trial NCT00082667?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.